505 related articles for article (PubMed ID: 9329513)
21. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
Antivir Ther; 1999; 4(1):45-9. PubMed ID: 10682128
[TBL] [Abstract][Full Text] [Related]
22. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
23. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
Coakley EP; Gillis JM; Hammer SM
AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
[TBL] [Abstract][Full Text] [Related]
25. Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
Flandre P
AIDS; 1999 Feb; 13(3):430-1. PubMed ID: 10199241
[No Abstract] [Full Text] [Related]
26. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
27. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
28. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Lallemant M; Ngo-Giang-Huong N; Jourdain G; Traisaithit P; Cressey TR; Collins IJ; Jarupanich T; Sukhumanant T; Achalapong J; Sabsanong P; Chotivanich N; Winiyakul N; Ariyadej S; Kanjanasing A; Ratanakosol J; Hemvuttiphan J; Kengsakul K; Wannapira W; Sittipiyasakul V; Pornkitprasarn W; Liampongsabuddhi P; McIntosh K; Van Dyke RB; Frenkel LM; Koetsawang S; Le Coeur S; Kanchana S;
Clin Infect Dis; 2010 Mar; 50(6):898-908. PubMed ID: 20158398
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC
J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
[TBL] [Abstract][Full Text] [Related]
31. The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.
Si Mohamed A; Kazatchkine M; Piketty C; Cotigny S; Gilquin J; Weiss L; Matta M; Gutmann L; Belec L
Antiviral Res; 1998 Jul; 39(1):47-53. PubMed ID: 9754949
[TBL] [Abstract][Full Text] [Related]
32. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
33. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
34. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
35. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
[TBL] [Abstract][Full Text] [Related]
38. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
[TBL] [Abstract][Full Text] [Related]
40. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
